PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19331204-2	2009	The primary endpoint evaluated in this study was whether interleukin-2 (IL-2) and 13-cisretinoic acid (RA) treatment reduced VEGF and improved immune function in such patients.	Isotretinoin	82-101	interleukin 2 receptor subunit alpha	Homo sapiens	103-105	
16767920-2	2003	We have demonstrated, in a phase IB study, that administering low-dose interleukin-2 (IL-2) and 13-cis retinoic acid (RA), there was a significant improvement of the immune function, with low toxicity, in PTS with advanced tumors that had been treated with aggressive surgery and chemotherapy (Clin Cancer Res 7: 1251-1257, 2001).	Isotretinoin	96-116	interleukin 2 receptor subunit alpha	Homo sapiens	118-120	
12012010-2	2002	13-cis retinoic acid (RA) has immunomodulatory properties, potentially synergistic with IL-2.	Isotretinoin	0-20	interleukin 2 receptor subunit alpha	Homo sapiens	22-24	
9067580-2	1997	Incubation of these cells for 48 h with either 13-cis retinoid acid (13-cis RA) or all-trans retinoic acid (ATRA) resulted in marked inhibition of cell growth, determined by 3H-thymidine incorporation, and in down-regulation of CD25 expression, determined by flow cytometry.	Isotretinoin	69-78	interleukin 2 receptor subunit alpha	Homo sapiens	228-232	
8952316-1	1996	We observed the effects of the retinoic acid (13-cis retinoic acid; 13-cis RA, and all-trans retinoic acid; ATRA) for the cell growth and the expression of CD 25 on peripheral blood mononuclear cells (PBMC) from 17 patients with adult T cell leukemia (ATL).	Isotretinoin	46-66	interleukin 2 receptor subunit alpha	Homo sapiens	156-161